---
title: "Genprex Raises $8.1 Million in Registered Direct Offering and Private Placement"
description: "Genprex Inc. has raised $8.1 million through a registered direct offering and a concurrent private placement. The registered offering includes the sale of 243,622 shares at $11.21 each, totaling appro"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262433356.md"
published_at: "2025-10-23T12:13:04.000Z"
---

# Genprex Raises $8.1 Million in Registered Direct Offering and Private Placement

> Genprex Inc. has raised $8.1 million through a registered direct offering and a concurrent private placement. The registered offering includes the sale of 243,622 shares at $11.21 each, totaling approximately $2.7 million. Additionally, the company will issue unregistered short-term warrants for up to 487,244 shares at an exercise price of $11.00, potentially generating an extra $5.4 million if fully exercised. The funds will be used for working capital and general corporate purposes, with H.C. Wainwright & Co. as the exclusive placement agent.

Genprex Inc., a clinical-stage gene therapy company, has announced a registered direct offering of approximately $2.7 million through the sale of 243,622 shares of common stock at $11.21 per share. In a concurrent private placement, the company will issue unregistered short-term warrants to purchase up to 487,244 shares of common stock at an exercise price of $11.00 per share. These warrants will be immediately exercisable and will expire 24 months after the effective date of a registration statement for the underlying shares. If fully exercised, the warrants could yield an additional $5.4 million in gross proceeds. Genprex plans to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA05439) on October 23, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [GNPX.US - Genprex](https://longbridge.com/en/quote/GNPX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股盘前热门交易：Genprex 盘前涨 8.01%；阿特斯太阳能盘前涨 3.02% | Genprex 盘前涨 8.01%；阿特斯太阳能盘前涨 3.02%；Springview 盘前涨 260.89%；Bonk 盘前涨 79.56%；authID 盘前涨 72.29%。 | [Link](https://longbridge.com/en/news/272706995.md) |
| Genprex 更新了其在纳斯达克合规方面的努力 | 2025 年 12 月 23 日，Genprex, Inc. 报告了其在纳斯达克合规方面的进展。主要亮点：Genprex 通过直接发行和信用额度筹集资金。公司认为其超过了纳斯达克的股本要求。纳斯达克小组尚未确认合规状态。在合规性得到验证之前 | [Link](https://longbridge.com/en/news/270613901.md) |
| 避险模式！大摩：市场开始买美债了 | 投资者对 AI“过度投资” 及其负面外部性的担忧加剧，导致 SaaS 及私募信贷相关股票承压。与此同时，美国年收入 10 万美元以上的富裕阶层消费者信心显著恶化，警示经济下行风险。叠加 1 月 CPI 数据意外疲软，资金正从风险资产撤出并涌 | [Link](https://longbridge.com/en/news/276025570.md) |
| 年终岁尾最后一刻，公募高管批量 “上下课” | 在年前的最后一个工作日，十多家公募基金宣布高管与董事长的变更，标志着公募行业的重要人事调整。泉果基金新任总经理李云亮接替离任的王国斌，博时基金副总经理王德英因岗位调整离任，合煦智远基金总经理李骥因个人原因离任但继续担任基金经理。这一系列变动 | [Link](https://longbridge.com/en/news/275973710.md) |
| 黑石入局、英伟达加持：澳洲 AI 公司获 100 亿美元融资，拟年内 IPO | Firmus 获得 100 亿美元贷款融资，这是该国规模最大的私募信贷融资交易之一，这笔融资由黑石集团牵头的基金提供，资金将用于 Firmus 数据中心扩张的下一阶段，而项目将采用英伟达的芯片。澳大利亚凭借丰富的资源和战略位置，正在全球 A | [Link](https://longbridge.com/en/news/275284915.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.